• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8/27/25 4:30:52 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email
    false 0001829247 0001829247 2025-08-21 2025-08-21 0001829247 BFRG:CommonStockParValue0.00001PerShareMember 2025-08-21 2025-08-21 0001829247 BFRG:TradeableWarrantsMember 2025-08-21 2025-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 21, 2025

     

    BULLFROG AI HOLDINGS, INC.

    (Exact name of Registrant as specified in its charter)

     

    Nevada   001-41600   84-4786155

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    325 Ellington Blvd, Unit 317

    Gaithersburg, MD 20878

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (240) 658-6710

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

      BFRG  

    The Nasdaq Stock Market LLC

    (The Nasdaq Capital Market)

    Tradeable Warrants   BFRGW  

    The Nasdaq Stock Market LLC

    (The Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On August 21, 2025, BullFrog AI Holdings, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, based on the Company’s stockholders’ equity of $2,188,110 as reported on its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholder Equity Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock and tradable warrants. As such, the Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “BFRG”, and its tradable warrants will continue to trade on the Nasdaq Capital Market under the symbol “BFRGW”.

     

    In accordance with Nasdaq’s listing rules, the Company has 45 calendar days to provide a plan to Nasdaq to regain compliance with the Stockholder Equity Requirement. If this plan is accepted by Nasdaq, the Company may be granted an extension of 180 calendar days from receipt of the deficiency letter to evidence compliance. If the Company is granted such extension and does not regain compliance with the Stockholder Equity Requirement by the end of the compliance period, the Company’s common stock and tradable warrants will become subject to delisting. In the event that the Company receives notice that its common stock and tradable warrants are being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Nasdaq’s staff to a Nasdaq hearings panel.

     

    The Company intends to take all reasonable measures available to regain compliance with the Nasdaq listing rules and remain listed on Nasdaq. The Company is currently evaluating various options to regain compliance and plans to timely submit a plan to Nasdaq to regain compliance with the Nasdaq Stockholder Equity Requirement. There can, however, be no assurance that the Company’s plan will be accepted by Nasdaq or that, if it is accepted, the Company will be able to regain compliance.

     

    Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On August 21, 2025, the Board of Directors of the Company approved refresh equity awards for the executive officers and directors of the Company. The awards are one-time compensatory and retention awards to the awardees for service to the Company during this critical time in the Company’s history and were made to supplement existing awards, as existing stock option awards are significantly underwater.

     

    The awards consist of a stock award, stock award with immediate vesting, equal to 33% of the total award and restricted stock units (“RSUs”) equal to 67% of the total award with vesting 50% on each of September 1, 2026 and September 1, 2027. The forfeiture restrictions on the RSUs will lapse in the event of a change in control of the Company or a significant financing that may, or may not, constitute a change in control.

     

    The awards were made under the Company’s 2022 Equity Compensation Plan. An aggregate of 267,842 shares underlie these awards if the RSUs fully vest.

     

    Cautionary Note regarding Forward-Looking Statements

     

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are intended to qualify for the safe harbor from liability established thereunder. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond the Company’s control, and that may cause results to differ materially from expectations. Examples of forward-looking statements include, among others, statements regarding the Company’s ability to regain compliance with Nasdaq rules. The forward-looking statements made in this report speak only as of the date of this report, and the Company assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 27, 2025 BullFrog AI Holdings, Inc.
         
      By: /s/ Vininder Singh
      Name: Vininder Singh
      Title: Chief Executive Officer

     

     

    Get the next $BFRG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRG
    SEC Filings

    View All

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    8/27/25 4:30:52 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Bullfrog AI Holdings Inc.

    10-Q - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    8/13/25 4:59:11 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Bullfrog AI Holdings Inc.

    DEF 14A - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    8/8/25 8:00:16 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Blacher Joshua was granted 15,000 shares (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    8/26/25 4:05:37 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Elsey R Don was granted 8,523 shares (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    8/26/25 4:05:35 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Singh Vininder was granted 75,000 shares, increasing direct ownership by 3% to 2,367,446 units (SEC Form 4)

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    8/26/25 4:05:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

    GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30. Fireside Presentation Details Date: Wednesday, July 30, 2025 Time: 11:20 a.m. ET To request access to the presentation, contact: USCorporat

    7/28/25 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development

    From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence In a $200B+ market crowded with black-box AI, BullFrog AI's bfLEAP™ delivers what others can't: biologically grounded, composition-aware analytics that guide smarter therapeutic decisions GAITHERSBURG, Md., July 22, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of a new white paper titled "Why

    7/22/25 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Join BullFrog AI's Exclusive Live Investor Webinar and Q&A Session on July 23

    GAITHERSBURG, Md., July 18, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics,, is pleased to invite investors to a webinar on July 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature BullFrog AI's Founder and CEO, Vin Singh. Attendees will gain insights into BullFrog AI's pioneering role in transforming drug discovery and development through its scalable, AI-driven platforms, including the newly launched BullFrog Data Netw

    7/18/25 9:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Announces Appointment of Chief Financial Officer

    GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and

    12/17/24 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

    GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea

    10/15/24 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Financials

    Live finance-specific insights

    View All

    BullFrog AI and GreenPower Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u

    4/26/24 9:00:00 AM ET
    $BFRG
    $GP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto

    10/27/23 9:00:00 AM ET
    $ASPI
    $BFRG
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology